Summit Therapeutics PLC (SMMT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Summit Therapeutics PLC (SMMT) has a cash flow conversion efficiency ratio of -0.224x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-92.74 Million) by net assets ($414.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Summit Therapeutics PLC (SMMT) net asset quality to measure how much of total assets are equity-financed.
Summit Therapeutics PLC - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Summit Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Summit Therapeutics PLC to evaluate the quality of earnings relative to operating cash generation.
Summit Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Summit Therapeutics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sichuan Kelun Pharmaceutical Co Ltd
SHE:002422
|
0.018x |
|
Lynas Rare Earths Limited
F:LYIC
|
0.041x |
|
Antero Midstream Partners LP
NYSE:AM
|
0.123x |
|
TTM Technologies Inc
NASDAQ:TTMI
|
0.052x |
|
JD LOGISTICS DL-000025
F:822
|
N/A |
|
Taiwan Union Technology
TWO:6274
|
-0.087x |
|
Prada S.p.A.
F:PRP
|
0.080x |
|
Medibank Private Ltd
AU:MPL
|
-0.085x |
Annual Cash Flow Conversion Efficiency for Summit Therapeutics PLC (2003–2025)
The table below shows the annual cash flow conversion efficiency of Summit Therapeutics PLC from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see Summit Therapeutics PLC (SMMT) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $488.98 Million | $-239.67 Million | -0.490x | -34.08% |
| 2024-12-31 | $310.64 Million | $-113.56 Million | -0.366x | +63.00% |
| 2023-12-31 | $61.48 Million | $-60.74 Million | -0.988x | -200.93% |
| 2022-12-31 | $103.25 Million | $-33.90 Million | -0.328x | +62.33% |
| 2021-12-31 | $61.74 Million | $-53.81 Million | -0.872x | -43.93% |
| 2020-12-31 | $58.36 Million | $-35.34 Million | -0.606x | -38.80% |
| 2019-12-31 | $61.12 Million | $-26.66 Million | -0.436x | +30.67% |
| 2018-12-31 | $55.79 Million | $-35.11 Million | -0.629x | +57.26% |
| 2017-12-31 | $13.98 Million | $-20.58 Million | -1.472x | +57.64% |
| 2016-12-31 | $-4.37 Million | $15.18 Million | -3.476x | -327.51% |
| 2015-12-31 | $30.10 Million | $-24.47 Million | -0.813x | +4.27% |
| 2014-12-31 | $19.53 Million | $-16.59 Million | -0.849x | +31.09% |
| 2013-12-31 | $7.85 Million | $-9.68 Million | -1.232x | -10.25% |
| 2012-12-31 | $4.50 Million | $-5.03 Million | -1.118x | -11.09% |
| 2011-12-31 | $3.78 Million | $-3.80 Million | -1.006x | -35.07% |
| 2010-12-31 | $5.82 Million | $-4.34 Million | -0.745x | -272.40% |
| 2009-12-31 | $13.22 Million | $-2.65 Million | -0.200x | +83.25% |
| 2008-12-31 | $12.33 Million | $-14.72 Million | -1.194x | -300.46% |
| 2007-12-31 | $54.08 Million | $-16.13 Million | -0.298x | -100.73% |
| 2006-12-31 | $40.11 Million | $-5.96 Million | -0.149x | -272.67% |
| 2005-12-31 | $23.38 Million | $-931.84K | -0.040x | -3655.45% |
| 2004-12-31 | $26.53 Million | $29.74K | 0.001x | +100.25% |
| 2003-12-31 | $142.31K | $-64.97K | -0.457x | -- |
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cance… Read more